Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Researchers reposition existing prazosin drug to combat glioblastoma

Researchers reposition existing prazosin drug to combat glioblastoma

Proteins can be used as targets to deliver drugs into stressed cancer cells

Proteins can be used as targets to deliver drugs into stressed cancer cells

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

Penn researchers report results of CAR therapy trial in brain cancer patients

Penn researchers report results of CAR therapy trial in brain cancer patients

Low-carbohydrate diet helps reduce growth of glioblastoma tumor cells in mouse models

Low-carbohydrate diet helps reduce growth of glioblastoma tumor cells in mouse models

Compound from unique blue-green algae could be key to next anti-cancer drug

Compound from unique blue-green algae could be key to next anti-cancer drug

Altered metabolism of two essential amino acids helps drive development of glioblastoma

Altered metabolism of two essential amino acids helps drive development of glioblastoma

Researchers develop metastasis-on-a-chip system to advance cancer investigation, drug discovery

Researchers develop metastasis-on-a-chip system to advance cancer investigation, drug discovery

Tews Laboratory uses LaVision BioTec UltraMicroscope to study molecular mechanisms of tumor invasion

Tews Laboratory uses LaVision BioTec UltraMicroscope to study molecular mechanisms of tumor invasion

Novel compound shows promise as potential treatment for acute myeloid leukemia

Novel compound shows promise as potential treatment for acute myeloid leukemia

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

Expression of BIRC3 protein associated with poor survival, recurrent disease in GBM patients

Expression of BIRC3 protein associated with poor survival, recurrent disease in GBM patients

Study provides critical insight into Warburg effect

Study provides critical insight into Warburg effect

U-M researchers develop novel mouse model of children's brain cancer

U-M researchers develop novel mouse model of children's brain cancer

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

UNC-Chapel Hill pharmacy researchers use skin cells to destroy brain tumors

UNC-Chapel Hill pharmacy researchers use skin cells to destroy brain tumors

Immunotherapy emerges as promising strategy for treatment of brain tumors

Immunotherapy emerges as promising strategy for treatment of brain tumors

Researchers identify common molecular alteration in glioblastoma

Researchers identify common molecular alteration in glioblastoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.